NASDAQ:LJPCLa Jolla Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.41 +0.40 (+7.98 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$5.39Now: $5.41▼$5.8850-Day Range$4.55MA: $6.65▼$7.8452-Week Range$2.30Now: $5.41▼$13.90Volume1.40 million shsAverage Volume845,610 shsMarket Capitalization$147.69 millionP/E RatioN/ADividend YieldN/ABeta2.5 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingLa Jolla Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.50, La Jolla Pharmaceutical has a potential upside of 260.4% from its current price of $5.41.Amount of Analyst CoverageLa Jolla Pharmaceutical has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesLa Jolla Pharmaceutical has received 356 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLa Jolla Pharmaceutical has received 322 “underperform” votes. (Add your “underperform” vote.)Community SentimentLa Jolla Pharmaceutical has received 52.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote “Outperform” if you believe LJPC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLa Jolla Pharmaceutical does not currently pay a dividend.Dividend GrowthLa Jolla Pharmaceutical does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, La Jolla Pharmaceutical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,319,135.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 33.39% of the stock of La Jolla Pharmaceutical is held by insiders.Percentage Held by Institutions79.25% of the stock of La Jolla Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for La Jolla Pharmaceutical are expected to grow in the coming year, from ($2.26) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of La Jolla Pharmaceutical is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of La Jolla Pharmaceutical is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.08 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LJPC Previous Symbol CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone858-207-4264Debt Debt-to-Equity RatioN/A Current Ratio5.37 Quick Ratio5.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.05 million Price / Sales6.41 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-2.45Profitability EPS (Most Recent Fiscal Year)($4.30) Net Income$-116,510,000.00 Net Margins-355.86% Return on EquityN/A Return on Assets-65.61%Miscellaneous Employees169 Outstanding Shares27,300,000Market Cap$147.69 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:LJPC Rates by TradingView Receive LJPC News and Ratings via Email Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter. La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions How has La Jolla Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LJPC shares have increased by 12.5% and is now trading at $5.41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of La Jolla Pharmaceutical? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for La Jolla Pharmaceutical. When is La Jolla Pharmaceutical's next earnings date? La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for La Jolla Pharmaceutical. How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.60. The biopharmaceutical company had revenue of $7.59 million for the quarter, compared to analysts' expectations of $8.50 million. View La Jolla Pharmaceutical's earnings history. What price target have analysts set for LJPC? 3 analysts have issued 1-year price objectives for La Jolla Pharmaceutical's shares. Their forecasts range from $19.00 to $20.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $19.50 in the next year. This suggests a possible upside of 260.4% from the stock's current price. View analysts' price targets for La Jolla Pharmaceutical. Has La Jolla Pharmaceutical been receiving favorable news coverage? News stories about LJPC stock have trended somewhat negative on Saturday, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a news impact score of -1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutLa Jolla Pharmaceutical. Who are some of La Jolla Pharmaceutical's key competitors? Some companies that are related to La Jolla Pharmaceutical include MeiraGTx (MGTX), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Innate Pharma (IPHYF), Scholar Rock (SRRK), Voyager Therapeutics (VYGR), Harpoon Therapeutics (HARP), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Verona Pharma (TARA), Tcr2 Therapeutics (TCRR), Eiger Biopharmaceuticals (EIGR), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI) and Cellular Biomedicine Group (CBMG). View all competitors. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), El Pollo LoCo (LOCO), Sarepta Therapeutics (SRPT), Neurocrine Biosciences (NBIX), Exelixis (EXEL), XOMA (XOMA), Juno Therapeutics (JUNO), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Who are La Jolla Pharmaceutical's key executives? La Jolla Pharmaceutical's management team includes the following people: Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)Mr. James M. Rolke, Chief Scientific Officer (Age 50)Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48) What is La Jolla Pharmaceutical's stock symbol? La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC." Who are La Jolla Pharmaceutical's major shareholders? La Jolla Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (29.60%), BlackRock Inc. (5.70%), Morgan Stanley (2.34%), Morgan Stanley (2.34%), State Street Corp (1.50%) and Geode Capital Management LLC (1.15%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla and Life Sciences Maste Perceptive. View institutional ownership trends for La Jolla Pharmaceutical. Which institutional investors are selling La Jolla Pharmaceutical stock? LJPC stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Geode Capital Management LLC, BlackRock Inc., State Street Corp, JPMorgan Chase & Co., Acadian Asset Management LLC, Parametric Portfolio Associates LLC, and UBS Group AG. View insider buying and selling activity for La Jolla Pharmaceutical. Which institutional investors are buying La Jolla Pharmaceutical stock? LJPC stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Morgan Stanley, Morgan Stanley, First Midwest Bank Trust Division, Two Sigma Investments LP, Premier Asset Management LLC, Engineers Gate Manager LP, and Deutsche Bank AG. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, and Lakhmir S Chawla. View insider buying and selling activity for La Jolla Pharmaceutical. How do I buy shares of La Jolla Pharmaceutical? Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is La Jolla Pharmaceutical's stock price today? One share of LJPC stock can currently be purchased for approximately $5.41. How big of a company is La Jolla Pharmaceutical? La Jolla Pharmaceutical has a market capitalization of $147.69 million and generates $23.05 million in revenue each year. The biopharmaceutical company earns $-116,510,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe. What is La Jolla Pharmaceutical's official website? The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com. How can I contact La Jolla Pharmaceutical? La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected] This page was last updated on 6/7/2020 by MarketBeat.com Staff
